Mode
Text Size
Log in / Sign up

Relapsed or refractory acute myeloid leukemia

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Primary Care & Family Medicine Meta-analysis
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL
Hematology Meta-analysis
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL Trial shows blinatumomab improves survival for pediatric B-cell leukemia
This meta-analysis of randomized trials found that adding blinatumomab to chemotherapy improved disease-free survival (RR 0.63) and overall …
Adding blinatumomab to chemotherapy may improve survival rates for children with specific types of high-risk or relapsed B-cell leukemia.
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma
Oncology Meta-analysis
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma Trial Shows Brexucabtagene Autoleucel Provides Durable Benefit for Blood Cancers
This meta-analysis of 31 cohorts evaluates brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma and B-cell acute lympho…
Brexucabtagene autoleucel shows high response rates and durable benefits for adults with specific types of relapsed or refractory blood canc…
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia
Pediatrics Meta-analysis
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia Exercise May Help Kids With Leukemia Feel and Move Better
This best evidence summary synthesizes 16 systematic reviews and 2 clinical practice guidelines regarding exercise interventions for childre…
Exercise may improve bone strength, fitness, and quality of life in children with acute leukemia, a new evidence summary suggests.
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
Hematology Sys. Review
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia
Oncology Meta-analysis
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia CAR-T Cells Show Promise for B-cell Acute Lymphoblastic Leukemia
This meta-analysis evaluates anti-CD19 shRNA-engineered CAR-T cells (interleukin-6 knockdown) for patients with B-cell acute lymphoblastic l…
New research into modified CAR-T cells shows high response rates in patients with a specific type of leukemia while managing serious side ef…
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
Allergy & Immunology Sys. Review
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Diabetes & Endocrinology Sys. Review
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing
Drug Pipeline Sys. Review
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing New review looks at using genetic tests to adjust cancer drug doses for kids
This narrative review examines the role of pharmacogenomic biomarkers and genotype-guided dose adjustments in pediatric B-cell acute lymphob…
A recent review suggests that checking specific genes before treatment can help doctors give the right amount of chemotherapy to children wi…
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response
Pediatrics Sys. Review
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response Boy with Down syndrome beats rare leukemia after tailored chemo
This narrative review and case report describes a 7-year-old boy with Down syndrome and T-cell acute lymphoblastic leukemia treated with AIE…
A 7-year-old with Down syndrome and a rare T-cell leukemia achieved remission after tailored chemotherapy, despite severe complications.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
Oncology Meta-analysis
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Oncology RCT
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…